{ "run": { "id": "cmnr13r6k03wbp658hy650dph", "region": "US", "assetId": "cmnr13r2z03w4p658bvgqla3i", "ticker": "FTV", "snapshotId": "cmnr13r4003w7p658p6ckr9cm", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:45.401Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr13r4003w7p658p6ckr9cm", "assetId": "cmnr13r2z03w4p658bvgqla3i", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 59.38, "dayLow": 57.915, "volume": 2303354, "dayHigh": 59.425, "currency": "USD", "prevClose": 56.87, "week52Low": 45.505, "week52High": 62.42 }, "fundamentals": { "pe": 31.7298850574713, "beta": 0.983704830113272, "epsTTM": 1.74, "fcfTTM": 879000000, "growth": { "epsYoy": -0.2719665271966528, "revenueYoy": -0.332600532751372 }, "sector": "Industrial Instruments For Measurement, Display, and Control", "margins": { "net": 0.1392608977903873, "gross": 0.6350171912192542, "operating": 0.1731624630328677 }, "website": "http://fortive.com", "industry": "Conglomerate", "pegRatio": -1.16668346595933, "ebitdaTTM": 926200000, "forwardPe": 18.652027027027, "marketCap": 18200000000, "totalCash": 375500000, "totalDebt": 4105500000, "debtEquity": 0.63617627917067, "quickRatio": 0.471423484376391, "revenueTTM": 4159100000, "companyName": "Fortive Corp", "priceToBook": 1.93125349011179, "currentRatio": 0.714724472536277, "dividendYield": 0.00503008229258276, "returnOnAssets": 0.04934527207204137, "returnOnEquity": 0.0897511389345151, "analystOpinions": null, "businessSummary": "Fortive Corporation is an American industrial technology conglomerate company headquartered in Everett, Washington. The company specializes in providing essential technologies for connected workflow solutions; designing, developing, manufacturing and distributing professional and engineered products, software and services. Their products and services are split into three strategic segments; Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. As of December 2022, Fortive has over 18,000 employees in 60 countries worldwide.", "enterpriseValue": 22059720000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 18000, "sharesOutstanding": 307859190, "enterpriseToEbitda": 23.81744763549989, "analystTargetMedian": null, "enterpriseToRevenue": 5.303964800076939, "operatingCashflowTTM": 1083200000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:45.312Z" }, "results": [ { "id": "cmnr13r6m03wdp658kjvi32wc", "runId": "cmnr13r6k03wbp658hy650dph", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"FTV\",\"currency\":\"USD\",\"current_price\":59.38,\"target_price_6m\":61.5,\"target_price_12m\":62.5,\"recommendation\":\"HOLD\",\"confidence\":0.55,\"thesis_bullets\":[\"Portfolio transformation toward higher-margin software/services businesses ongoing\",\"Revenue decline of ~33% YoY reflects major divestiture, complicating trend analysis\",\"Strong FCF generation at ~$879M supports debt reduction and capital allocation\",\"EV/EBITDA of 23.8x is elevated versus industrial peers, limiting upside\",\"Forward P/E of 18.7x implies significant earnings recovery already priced in\"],\"key_drivers\":[{\"driver\":\"Portfolio mix shift toward recurring revenue and software\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Post-divestiture organic growth trajectory unclear\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"FCF conversion supporting deleveraging from $4.1B debt\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Gross margins at 63.5% reflect high-quality business mix\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated valuation multiples limit margin of safety\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Macro/industrial cycle sensitivity with beta near 1.0\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Operating margin expansion potential from Fortive Business System\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Low current ratio (0.71) indicates tight near-term liquidity\",\"impact\":\"LOW\",\"direction\":\"NEG\"}],\"risks\":[\"Organic revenue growth disappoints on slimmed-down portfolio\",\"Multiple compression if earnings recovery falls short of forward estimates\",\"Rising interest costs on $4.1B debt burden in higher-rate environment\",\"Industrial end-market slowdown pressures Precision Technologies segment\",\"Integration or execution missteps in portfolio transformation strategy\"],\"assumptions\":{\"revenue_cagr_3y\":0.04,\"ebit_margin_target\":0.20,\"wacc\":0.09,\"terminal_multiple\":20.0},\"scenarios\":{\"bear\":{\"target_price\":50.0,\"prob\":0.20,\"notes\":\"Economic slowdown drives multiple compression and organic revenue declines.\"},\"base\":{\"target_price\":62.5,\"prob\":0.55,\"notes\":\"Modest organic growth and margin expansion on transformed portfolio; multiples stable.\"},\"bull\":{\"target_price\":72.0,\"prob\":0.25,\"notes\":\"Accelerating software/recurring revenue drives re-rating toward software-like multiples.\"}},\"method_notes\":\"Blended valuation using forward P/E (18-20x on ~$3.20 forward EPS) and EV/EBITDA comps for diversified industrials with software exposure. Revenue CAGR assumes low-single-digit organic growth on post-divestiture base. Elevated current multiples and mixed macro signals yield ~5% expected return, placing FTV in HOLD territory. Probability-weighted scenario value (~$62.3) aligns with 12M target. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Organic revenue growth disappoints on slimmed-down portfolio", "Multiple compression if earnings recovery falls short of forward estimates", "Rising interest costs on $4.1B debt burden in higher-rate environment", "Industrial end-market slowdown pressures Precision Technologies segment", "Integration or execution missteps in portfolio transformation strategy" ], "ticker": "FTV", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Modest organic growth and margin expansion on transformed portfolio; multiples stable.", "target_price": 62.5 }, "bear": { "prob": 0.2, "notes": "Economic slowdown drives multiple compression and organic revenue declines.", "target_price": 50 }, "bull": { "prob": 0.25, "notes": "Accelerating software/recurring revenue drives re-rating toward software-like multiples.", "target_price": 72 } }, "confidence": 0.55, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.04, "terminal_multiple": 20, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "Portfolio mix shift toward recurring revenue and software", "impact": "HIGH", "direction": "POS" }, { "driver": "Post-divestiture organic growth trajectory unclear", "impact": "HIGH", "direction": "NEG" }, { "driver": "FCF conversion supporting deleveraging from $4.1B debt", "impact": "MED", "direction": "POS" }, { "driver": "Gross margins at 63.5% reflect high-quality business mix", "impact": "MED", "direction": "POS" }, { "driver": "Elevated valuation multiples limit margin of safety", "impact": "HIGH", "direction": "NEG" }, { "driver": "Macro/industrial cycle sensitivity with beta near 1.0", "impact": "MED", "direction": "NEG" }, { "driver": "Operating margin expansion potential from Fortive Business System", "impact": "MED", "direction": "POS" }, { "driver": "Low current ratio (0.71) indicates tight near-term liquidity", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Blended valuation using forward P/E (18-20x on ~$3.20 forward EPS) and EV/EBITDA comps for diversified industrials with software exposure. Revenue CAGR assumes low-single-digit organic growth on post-divestiture base. Elevated current multiples and mixed macro signals yield ~5% expected return, placing FTV in HOLD territory. Probability-weighted scenario value (~$62.3) aligns with 12M target. Not investment advice.", "current_price": 59.38, "recommendation": "HOLD", "thesis_bullets": [ "Portfolio transformation toward higher-margin software/services businesses ongoing", "Revenue decline of ~33% YoY reflects major divestiture, complicating trend analysis", "Strong FCF generation at ~$879M supports debt reduction and capital allocation", "EV/EBITDA of 23.8x is elevated versus industrial peers, limiting upside", "Forward P/E of 18.7x implies significant earnings recovery already priced in" ], "target_price_6m": 61.5, "target_price_12m": 62.5 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 40064, "createdAt": "2026-04-09T05:20:45.401Z", "usage": { "inputTokens": 3622, "outputTokens": 1896, "costUsd": 0.06551 } }, { "id": "cmnr13r6m03wgp658m8vroaqe", "runId": "cmnr13r6k03wbp658hy650dph", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI_Equity_Model_v1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"FTV\",\n \"currency\": \"USD\",\n \"current_price\": 59.38,\n \"target_price_6m\": 65.00,\n \"target_price_12m\": 70.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Diversified industrial tech with strong market positions.\",\n \"Forward earnings growth expected despite past declines.\",\n \"Healthy margins and robust cash flow generation.\",\n \"Strategic focus on connected workflow solutions.\",\n \"Valuation discounts future recovery potential.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Economic growth in industrial sectors\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Technological adoption in measurement and control\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Debt burden and interest costs\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Competition from other tech conglomerates\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Acquisition integration and synergy realization\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Regulatory changes in healthcare technology\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Global supply chain stability\", \"impact\": \"MED\", \"direction\": \"POS\" }\n ],\n \"risks\": [\n \"Economic recession reducing capital expenditure.\",\n \"Failure to innovate in key segments.\",\n \"Increased debt leading to financial stress.\",\n \"Foreign exchange volatility.\",\n \"Operational disruptions.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.03,\n \"ebit_margin_target\": 0.175,\n \"wacc\": 0.09,\n \"terminal_multiple\": 15.0\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 55.00, \"prob\": 0.3, \"notes\": \"Economic downturn and poor execution.\" },\n \"base\": { \"target_price\": 70.00, \"prob\": 0.5, \"notes\": \"Steady recovery and margin improvement.\" },\n \"bull\": { \"target_price\": 85.00, \"prob\": 0.2, \"notes\": \"Strong economic growth and successful innovations.\" }\n },\n \"method_notes\": \"Valuation based on forward earnings growth and sector multiples. Expected return ~18% supports BUY. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI_Equity_Model_v1", "risks": [ "Economic recession reducing capital expenditure.", "Failure to innovate in key segments.", "Increased debt leading to financial stress.", "Foreign exchange volatility.", "Operational disruptions." ], "ticker": "FTV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady recovery and margin improvement.", "target_price": 70 }, "bear": { "prob": 0.3, "notes": "Economic downturn and poor execution.", "target_price": 55 }, "bull": { "prob": 0.2, "notes": "Strong economic growth and successful innovations.", "target_price": 85 } }, "confidence": 0.65, "assumptions": { "wacc": 0.09, "revenue_cagr_3y": 0.03, "terminal_multiple": 15, "ebit_margin_target": 0.175 }, "key_drivers": [ { "driver": "Economic growth in industrial sectors", "impact": "HIGH", "direction": "POS" }, { "driver": "Technological adoption in measurement and control", "impact": "MED", "direction": "POS" }, { "driver": "Debt burden and interest costs", "impact": "MED", "direction": "NEG" }, { "driver": "Competition from other tech conglomerates", "impact": "LOW", "direction": "NEG" }, { "driver": "Acquisition integration and synergy realization", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory changes in healthcare technology", "impact": "LOW", "direction": "NEG" }, { "driver": "Global supply chain stability", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on forward earnings growth and sector multiples. Expected return ~18% supports BUY. Not investment advice.", "current_price": 59.38, "recommendation": "BUY", "thesis_bullets": [ "Diversified industrial tech with strong market positions.", "Forward earnings growth expected despite past declines.", "Healthy margins and robust cash flow generation.", "Strategic focus on connected workflow solutions.", "Valuation discounts future recovery potential." ], "target_price_6m": 65, "target_price_12m": 70 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 352, "createdAt": "2026-04-09T05:20:45.401Z", "usage": { "inputTokens": 2127, "outputTokens": 3901, "costUsd": 0.002234 } }, { "id": "cmnr13r6m03wep658zy5cajrn", "runId": "cmnr13r6k03wbp658hy650dph", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research Analyst AI\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"FTV\",\n \"currency\": \"USD\",\n \"current_price\": 59.38,\n \"target_price_6m\": 64.5,\n \"target_price_12m\": 70.2,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.72,\n \"thesis_bullets\": [\n \"Strategic shift toward high-margin software and recurring revenue improves earnings quality.\",\n \"Strong free cash flow generation supports disciplined, accretive bolt-on acquisition strategy.\",\n \"Advanced Healthcare segment provides defensive growth and significant margin expansion potential.\",\n \"Intelligent Operating Solutions benefits from secular trends in industrial automation and IoT.\",\n \"Current valuation at 18.6x forward P/E is attractive relative to historical industrial-tech peers.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"SaaS and Recurring Revenue Mix\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Industrial CAPEX Spending\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"M&A Integration and Synergy Realization\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Healthcare Segment Operating Margins\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Global Supply Chain Stability\",\n \"impact\": \"LOW\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest Rate Environment\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Macroeconomic slowdown impacting cyclical industrial demand.\",\n \"Execution risk related to the integration of large acquisitions.\",\n \"Intense competition in the precision technologies and measurement space.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 5.5,\n \"ebit_margin_target\": 25.0,\n \"wacc\": 8.8,\n \"terminal_multiple\": 16.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 51.5,\n \"prob\": 0.2,\n \"notes\": \"Recession leads to significant contraction in industrial and precision technology segments.\"\n },\n \"base\": {\n \"target_price\": 70.2,\n \"prob\": 0.6,\n \"notes\": \"Steady execution on software transition and moderate organic growth in healthcare.\"\n },\n \"bull\": {\n \"target_price\": 82.0,\n \"prob\": 0.2,\n \"notes\": \"Accelerated margin expansion and highly accretive M&A drive valuation multiple re-rating.\"\n }\n },\n \"method_notes\": \"Valuation derived from a blend of 21x forward P/E and a 10-year DCF model. BUY recommendation is supported by an expected 18% total return, driven by the portfolio's shift toward higher-margin software services. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Equity Research Analyst AI", "risks": [ "Macroeconomic slowdown impacting cyclical industrial demand.", "Execution risk related to the integration of large acquisitions.", "Intense competition in the precision technologies and measurement space." ], "ticker": "FTV", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady execution on software transition and moderate organic growth in healthcare.", "target_price": 70.2 }, "bear": { "prob": 0.2, "notes": "Recession leads to significant contraction in industrial and precision technology segments.", "target_price": 51.5 }, "bull": { "prob": 0.2, "notes": "Accelerated margin expansion and highly accretive M&A drive valuation multiple re-rating.", "target_price": 82 } }, "confidence": 0.72, "assumptions": { "wacc": 8.8, "revenue_cagr_3y": 5.5, "terminal_multiple": 16.5, "ebit_margin_target": 25 }, "key_drivers": [ { "driver": "SaaS and Recurring Revenue Mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Industrial CAPEX Spending", "impact": "MED", "direction": "POS" }, { "driver": "M&A Integration and Synergy Realization", "impact": "MED", "direction": "POS" }, { "driver": "Healthcare Segment Operating Margins", "impact": "MED", "direction": "POS" }, { "driver": "Global Supply Chain Stability", "impact": "LOW", "direction": "POS" }, { "driver": "Interest Rate Environment", "impact": "LOW", "direction": "NEG" } ], "method_notes": "Valuation derived from a blend of 21x forward P/E and a 10-year DCF model. BUY recommendation is supported by an expected 18% total return, driven by the portfolio's shift toward higher-margin software services. Not investment advice.", "current_price": 59.38, "recommendation": "BUY", "thesis_bullets": [ "Strategic shift toward high-margin software and recurring revenue improves earnings quality.", "Strong free cash flow generation supports disciplined, accretive bolt-on acquisition strategy.", "Advanced Healthcare segment provides defensive growth and significant margin expansion potential.", "Intelligent Operating Solutions benefits from secular trends in industrial automation and IoT.", "Current valuation at 18.6x forward P/E is attractive relative to historical industrial-tech peers." ], "target_price_6m": 64.5, "target_price_12m": 70.2 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 10798, "createdAt": "2026-04-09T05:20:45.401Z", "usage": { "inputTokens": 2489, "outputTokens": 797, "costUsd": 0.014542 } }, { "id": "cmnr13r6m03wcp658h7i4dfna", "runId": "cmnr13r6k03wbp658hy650dph", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"FTV\",\"currency\":\"USD\",\"current_price\":59.38,\"target_price_6m\":60.8,\"target_price_12m\":62,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"High gross margins and solid FCF support resilience through softer industrial demand.\",\"Forward P/E is reasonable, but EV/EBITDA remains rich for current growth.\",\"Portfolio simplification and software mix can lift margins over 12-24 months.\",\"Recent revenue and EPS declines temper near-term upside and lower conviction.\",\"Net result is near-fair-value shares with modest upside, fitting HOLD.\"],\"key_drivers\":[{\"driver\":\"Recurring software and service mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Fortive Business System margin gains\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Portfolio simplification and M&A\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Healthcare and workflow demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Cash conversion and deleveraging\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Weak industrial end markets\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Elevated EV/EBITDA valuation\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Execution and FX headwinds\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Organic growth stays negative longer than expected.\",\"Multiple compresses as rates remain higher.\",\"Integration or separation execution missteps.\",\"Healthcare and industrial orders weaken further.\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.215,\"wacc\":0.085,\"terminal_multiple\":18},\"scenarios\":{\"bear\":{\"target_price\":50,\"prob\":0.25,\"notes\":\"Demand stays soft and valuation de-rates on slower recovery.\"},\"base\":{\"target_price\":62,\"prob\":0.5,\"notes\":\"Moderate growth resumes and margin expansion offsets valuation pressure.\"},\"bull\":{\"target_price\":74,\"prob\":0.25,\"notes\":\"Stronger software mix and execution drive faster EPS growth.\"}},\"method_notes\":\"12M target uses a blended forward earnings and EV/EBIT approach on snapshot fundamentals, cross-checked with scenario weighting; no sell-side targets used. Quality, FCF and margin potential offset weak recent growth and rich EV/EBITDA, leaving only modest upside, so HOLD. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Model Recommendation v2", "risks": [ "Organic growth stays negative longer than expected.", "Multiple compresses as rates remain higher.", "Integration or separation execution missteps.", "Healthcare and industrial orders weaken further." ], "ticker": "FTV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Moderate growth resumes and margin expansion offsets valuation pressure.", "target_price": 62 }, "bear": { "prob": 0.25, "notes": "Demand stays soft and valuation de-rates on slower recovery.", "target_price": 50 }, "bull": { "prob": 0.25, "notes": "Stronger software mix and execution drive faster EPS growth.", "target_price": 74 } }, "confidence": 0.63, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.055, "terminal_multiple": 18, "ebit_margin_target": 0.215 }, "key_drivers": [ { "driver": "Recurring software and service mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Fortive Business System margin gains", "impact": "HIGH", "direction": "POS" }, { "driver": "Portfolio simplification and M&A", "impact": "MED", "direction": "POS" }, { "driver": "Healthcare and workflow demand", "impact": "MED", "direction": "POS" }, { "driver": "Cash conversion and deleveraging", "impact": "MED", "direction": "POS" }, { "driver": "Weak industrial end markets", "impact": "HIGH", "direction": "NEG" }, { "driver": "Elevated EV/EBITDA valuation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Execution and FX headwinds", "impact": "MED", "direction": "NEG" } ], "method_notes": "12M target uses a blended forward earnings and EV/EBIT approach on snapshot fundamentals, cross-checked with scenario weighting; no sell-side targets used. Quality, FCF and margin potential offset weak recent growth and rich EV/EBITDA, leaving only modest upside, so HOLD. not investment advice", "current_price": 59.38, "recommendation": "HOLD", "thesis_bullets": [ "High gross margins and solid FCF support resilience through softer industrial demand.", "Forward P/E is reasonable, but EV/EBITDA remains rich for current growth.", "Portfolio simplification and software mix can lift margins over 12-24 months.", "Recent revenue and EPS declines temper near-term upside and lower conviction.", "Net result is near-fair-value shares with modest upside, fitting HOLD." ], "target_price_6m": 60.8, "target_price_12m": 62 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_096f5e130d9972620069d75939e8e08196a23939d307ed433e", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 45820, "createdAt": "2026-04-09T05:20:45.401Z", "usage": { "inputTokens": 2398, "outputTokens": 2566, "costUsd": 0.04012 } }, { "id": "cmnr13r6m03wfp658y063j5qa", "runId": "cmnr13r6k03wbp658hy650dph", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"DCF Scenario Valuation Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"FTV\",\n \"currency\": \"USD\",\n \"current_price\": 59.38,\n \"target_price_6m\": 62.5,\n \"target_price_12m\": 68.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.61,\n \"thesis_bullets\": [\n \"Strong 63.5% gross margins despite revenue dip\",\n \"Forward PE 18.7 signals expected earnings rebound\",\n \"Diversified portfolio across precision and healthcare\",\n \"Solid FCF generation of $879M aids balance sheet\",\n \"Cyclical headwinds and high debt pose near-term risks\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Industrial demand recovery\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Recent revenue contraction\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Margin expansion in key segments\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Innovation in operating solutions\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Elevated leverage levels\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Valuation on forward metrics\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Healthcare solutions growth\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Macro cyclical exposure\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Prolonged industrial slowdown\",\n \"FX volatility in global sales\",\n \"Competition in precision tech\",\n \"Debt servicing in high rate env\",\n \"Acquisition integration issues\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.055,\n \"ebit_margin_target\": 0.195,\n \"wacc\": 0.085,\n \"terminal_multiple\": 19\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 50.0,\n \"prob\": 0.25,\n \"notes\": \"Extended cyclical weakness and margin erosion.\"\n },\n \"base\": {\n \"target_price\": 68.0,\n \"prob\": 0.5,\n \"notes\": \"Gradual demand recovery matching forward guidance.\"\n },\n \"bull\": {\n \"target_price\": 83.0,\n \"prob\": 0.25,\n \"notes\": \"Accelerated growth from tech adoption and margins.\"\n }\n },\n \"method_notes\": \"3-stage DCF using revenue CAGR, EBIT target, WACC and terminal EV/EBIT multiple; weighted scenarios yield 14% upside. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "DCF Scenario Valuation Model", "risks": [ "Prolonged industrial slowdown", "FX volatility in global sales", "Competition in precision tech", "Debt servicing in high rate env", "Acquisition integration issues" ], "ticker": "FTV", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Gradual demand recovery matching forward guidance.", "target_price": 68 }, "bear": { "prob": 0.25, "notes": "Extended cyclical weakness and margin erosion.", "target_price": 50 }, "bull": { "prob": 0.25, "notes": "Accelerated growth from tech adoption and margins.", "target_price": 83 } }, "confidence": 0.61, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.055, "terminal_multiple": 19, "ebit_margin_target": 0.195 }, "key_drivers": [ { "driver": "Industrial demand recovery", "impact": "HIGH", "direction": "POS" }, { "driver": "Recent revenue contraction", "impact": "HIGH", "direction": "NEG" }, { "driver": "Margin expansion in key segments", "impact": "MED", "direction": "POS" }, { "driver": "Innovation in operating solutions", "impact": "MED", "direction": "POS" }, { "driver": "Elevated leverage levels", "impact": "MED", "direction": "NEG" }, { "driver": "Valuation on forward metrics", "impact": "MED", "direction": "POS" }, { "driver": "Healthcare solutions growth", "impact": "MED", "direction": "POS" }, { "driver": "Macro cyclical exposure", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "3-stage DCF using revenue CAGR, EBIT target, WACC and terminal EV/EBIT multiple; weighted scenarios yield 14% upside. not investment advice.", "current_price": 59.38, "recommendation": "BUY", "thesis_bullets": [ "Strong 63.5% gross margins despite revenue dip", "Forward PE 18.7 signals expected earnings rebound", "Diversified portfolio across precision and healthcare", "Solid FCF generation of $879M aids balance sheet", "Cyclical headwinds and high debt pose near-term risks" ], "target_price_6m": 62.5, "target_price_12m": 68 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "407e7371-b9b1-9c0d-9d43-96d58cb718e2", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 20834, "createdAt": "2026-04-09T05:20:45.401Z", "usage": { "inputTokens": 2738, "outputTokens": 3476, "costUsd": 0.060354 } } ] } }